GlycA Levels during the Earliest Stages of Rheumatoid Arthritis: Potential Use as a Biomarker of Subclinical Cardiovascular Disease
This study aimed at evaluating the clinical relevance of glycoprotein profiles during the earliest phases of rheumatoid arthritis (RA) as biomarkers of cardiovascular (CV) risk and treatment response. Then, GlycA and GlycB serum levels were measured using 1H-nuclear magnetic resonance in 82 early RA...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2020-08-01
|
| Series: | Journal of Clinical Medicine |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2077-0383/9/8/2472 |
| _version_ | 1797560595993591808 |
|---|---|
| author | Javier Rodríguez-Carrio Mercedes Alperi-López Patricia López Ángel I. Pérez-Álvarez Miriam Gil-Serret Núria Amigó Catalina Ulloa Lorena Benavente Francisco J. Ballina-García Ana Suárez |
| author_facet | Javier Rodríguez-Carrio Mercedes Alperi-López Patricia López Ángel I. Pérez-Álvarez Miriam Gil-Serret Núria Amigó Catalina Ulloa Lorena Benavente Francisco J. Ballina-García Ana Suárez |
| author_sort | Javier Rodríguez-Carrio |
| collection | DOAJ |
| description | This study aimed at evaluating the clinical relevance of glycoprotein profiles during the earliest phases of rheumatoid arthritis (RA) as biomarkers of cardiovascular (CV) risk and treatment response. Then, GlycA and GlycB serum levels were measured using 1H-nuclear magnetic resonance in 82 early RA patients, 14 clinically-suspect arthralgia (CSA), and 28 controls. Serum glycosyltransferase activity was assessed by a colorimetric assay. Subclinical CV disease was assessed by Doppler-ultrasound. We found that GlycA and GlycB serum levels were increased in RA (both <i>p</i> < 0.001), but not in CSA, independently of cardiometabolic risk factors. Increased serum glycosyltransferase activity paralleled GlycA (r = 0.405, <i>p</i> < 0.001) and GlycB levels (r = 0.327, <i>p</i> = 0.005) in RA. GlycA, but not GlycB, was associated with atherosclerosis occurrence (<i>p</i> = 0.012) and severity (<i>p</i> = 0.001). Adding GlycA to the mSCORE improved the identification of patients with atherosclerosis over mSCORE alone, increasing sensitivity (29.7 vs. 68.0%) and accuracy (55.8 vs. 76.6%) and allowing reclassification into more appropriate risk categories. GlycA-reclassification identified patients with impaired lipoprotein metabolism. Finally, baseline GlycA levels predicted poor clinical response upon anti-rheumatic treatment at 6 and 12 months in univariate and multivariate analysis. In sum, increased GlycA levels during the earliest stage of RA can be considered a powerful biomarker for CV risk stratification and treatment response. |
| first_indexed | 2024-03-10T18:01:57Z |
| format | Article |
| id | doaj.art-36bee7c4675f46f0ba6350ea9451612e |
| institution | Directory Open Access Journal |
| issn | 2077-0383 |
| language | English |
| last_indexed | 2024-03-10T18:01:57Z |
| publishDate | 2020-08-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Journal of Clinical Medicine |
| spelling | doaj.art-36bee7c4675f46f0ba6350ea9451612e2023-11-20T08:45:31ZengMDPI AGJournal of Clinical Medicine2077-03832020-08-0198247210.3390/jcm9082472GlycA Levels during the Earliest Stages of Rheumatoid Arthritis: Potential Use as a Biomarker of Subclinical Cardiovascular DiseaseJavier Rodríguez-Carrio0Mercedes Alperi-López1Patricia López2Ángel I. Pérez-Álvarez3Miriam Gil-Serret4Núria Amigó5Catalina Ulloa6Lorena Benavente7Francisco J. Ballina-García8Ana Suárez9Area of Immunology, Department of Functional Biology, Faculty of Medicine, University of Oviedo, 33006 Oviedo, SpainInstituto de Investigación Sanitaria del Principado de Asturias (ISPA), 33011 Oviedo, SpainArea of Immunology, Department of Functional Biology, Faculty of Medicine, University of Oviedo, 33006 Oviedo, SpainDepartment of Neurology, Hospital Universitario Central de Asturias, 33011 Oviedo, SpainBiosfer Teslab, SL, 43201 Reus, SpainBiosfer Teslab, SL, 43201 Reus, SpainBone and Mineral Research Unit, Instituto Reina Sofía de Investigación Nefrológica, REDinREN del ISCIII, Hospital Universitario Central de Asturias, 33011 Oviedo, SpainDepartment of Neurology, Hospital Universitario Central de Asturias, 33011 Oviedo, SpainInstituto de Investigación Sanitaria del Principado de Asturias (ISPA), 33011 Oviedo, SpainArea of Immunology, Department of Functional Biology, Faculty of Medicine, University of Oviedo, 33006 Oviedo, SpainThis study aimed at evaluating the clinical relevance of glycoprotein profiles during the earliest phases of rheumatoid arthritis (RA) as biomarkers of cardiovascular (CV) risk and treatment response. Then, GlycA and GlycB serum levels were measured using 1H-nuclear magnetic resonance in 82 early RA patients, 14 clinically-suspect arthralgia (CSA), and 28 controls. Serum glycosyltransferase activity was assessed by a colorimetric assay. Subclinical CV disease was assessed by Doppler-ultrasound. We found that GlycA and GlycB serum levels were increased in RA (both <i>p</i> < 0.001), but not in CSA, independently of cardiometabolic risk factors. Increased serum glycosyltransferase activity paralleled GlycA (r = 0.405, <i>p</i> < 0.001) and GlycB levels (r = 0.327, <i>p</i> = 0.005) in RA. GlycA, but not GlycB, was associated with atherosclerosis occurrence (<i>p</i> = 0.012) and severity (<i>p</i> = 0.001). Adding GlycA to the mSCORE improved the identification of patients with atherosclerosis over mSCORE alone, increasing sensitivity (29.7 vs. 68.0%) and accuracy (55.8 vs. 76.6%) and allowing reclassification into more appropriate risk categories. GlycA-reclassification identified patients with impaired lipoprotein metabolism. Finally, baseline GlycA levels predicted poor clinical response upon anti-rheumatic treatment at 6 and 12 months in univariate and multivariate analysis. In sum, increased GlycA levels during the earliest stage of RA can be considered a powerful biomarker for CV risk stratification and treatment response.https://www.mdpi.com/2077-0383/9/8/2472glycoproteinsearly rheumatoid arthritiscardiovascular riskatherosclerosisinflammationH-NMR |
| spellingShingle | Javier Rodríguez-Carrio Mercedes Alperi-López Patricia López Ángel I. Pérez-Álvarez Miriam Gil-Serret Núria Amigó Catalina Ulloa Lorena Benavente Francisco J. Ballina-García Ana Suárez GlycA Levels during the Earliest Stages of Rheumatoid Arthritis: Potential Use as a Biomarker of Subclinical Cardiovascular Disease Journal of Clinical Medicine glycoproteins early rheumatoid arthritis cardiovascular risk atherosclerosis inflammation H-NMR |
| title | GlycA Levels during the Earliest Stages of Rheumatoid Arthritis: Potential Use as a Biomarker of Subclinical Cardiovascular Disease |
| title_full | GlycA Levels during the Earliest Stages of Rheumatoid Arthritis: Potential Use as a Biomarker of Subclinical Cardiovascular Disease |
| title_fullStr | GlycA Levels during the Earliest Stages of Rheumatoid Arthritis: Potential Use as a Biomarker of Subclinical Cardiovascular Disease |
| title_full_unstemmed | GlycA Levels during the Earliest Stages of Rheumatoid Arthritis: Potential Use as a Biomarker of Subclinical Cardiovascular Disease |
| title_short | GlycA Levels during the Earliest Stages of Rheumatoid Arthritis: Potential Use as a Biomarker of Subclinical Cardiovascular Disease |
| title_sort | glyca levels during the earliest stages of rheumatoid arthritis potential use as a biomarker of subclinical cardiovascular disease |
| topic | glycoproteins early rheumatoid arthritis cardiovascular risk atherosclerosis inflammation H-NMR |
| url | https://www.mdpi.com/2077-0383/9/8/2472 |
| work_keys_str_mv | AT javierrodriguezcarrio glycalevelsduringtheearlieststagesofrheumatoidarthritispotentialuseasabiomarkerofsubclinicalcardiovasculardisease AT mercedesalperilopez glycalevelsduringtheearlieststagesofrheumatoidarthritispotentialuseasabiomarkerofsubclinicalcardiovasculardisease AT patricialopez glycalevelsduringtheearlieststagesofrheumatoidarthritispotentialuseasabiomarkerofsubclinicalcardiovasculardisease AT angeliperezalvarez glycalevelsduringtheearlieststagesofrheumatoidarthritispotentialuseasabiomarkerofsubclinicalcardiovasculardisease AT miriamgilserret glycalevelsduringtheearlieststagesofrheumatoidarthritispotentialuseasabiomarkerofsubclinicalcardiovasculardisease AT nuriaamigo glycalevelsduringtheearlieststagesofrheumatoidarthritispotentialuseasabiomarkerofsubclinicalcardiovasculardisease AT catalinaulloa glycalevelsduringtheearlieststagesofrheumatoidarthritispotentialuseasabiomarkerofsubclinicalcardiovasculardisease AT lorenabenavente glycalevelsduringtheearlieststagesofrheumatoidarthritispotentialuseasabiomarkerofsubclinicalcardiovasculardisease AT franciscojballinagarcia glycalevelsduringtheearlieststagesofrheumatoidarthritispotentialuseasabiomarkerofsubclinicalcardiovasculardisease AT anasuarez glycalevelsduringtheearlieststagesofrheumatoidarthritispotentialuseasabiomarkerofsubclinicalcardiovasculardisease |